Patient characteristics at inclusion
| Variable | N=1698, n (%) | Missing, n |
|---|---|---|
| Gender | 0 | |
| Female | 852 (50.2) | |
| Male | 846 (49.8) | |
| Education (years) | 20 | |
| <10 | 544 (32) | |
| 10–12 | 700 (42) | |
| >12 | 434 (26) | |
| Living situation | 7 | |
| Alone | 349 (21) | |
| With spouse/partner | 737 (43) | |
| With spouse/partner and children | 376 (22) | |
| With others (children or adults) | 210 (13) | |
| In an institution | 19 (1) | |
| Country | 0 | |
| Australia, 1 site | 35 (2) | |
| Belgium, 1 site | 95 (6) | |
| Bulgaria, 1 site | 28 (2) | |
| Canada, 2 sites | 94 (6) | |
| Denmark, 2 sites | 100 (6) | |
| Georgia, 1 site | 19 (1) | |
| Italy, 7 sites | 605 (35) | |
| Norway, 4 sites | 235 (14) | |
| Portugal, 1 site | 58 (3) | |
| Spain, 4 sites | 233 (14) | |
| Switzerland, 2 sites | 68 (4) | |
| UK, 4 sites | 128 (7) | |
| Treatment setting | 38 | |
| Inpatients | 348 (21) | |
| Outpatients | 1017 (61) | |
| Home care | 295 (18) | |
| Comorbidity (numbers) | 5 | |
| 0 | 679 (40) | |
| 1 | 638 (39) | |
| 2 | 283 (16) | |
| 3 or more | 93 (5) | |
| Primary cancer diagnosis* | 4 | |
| Digestive organs | 520 (31) | |
| Respiratory organs† | 343 (20) | |
| Breast cancer | 284 (17) | |
| Male genital organs | 126 (7) | |
| Gynaecological | 99 (6) | |
| Urinary | 75 (4) | |
| Head | 58 (4) | |
| Leukaemia or lymphoma | 44 (3) | |
| Malignant connective/soft-tissue tumours | 40 (2) | |
| Skin cancer/malignant melanoma | 36 (2) | |
| CNS tumours | 24 (1) | |
| Secondary/ill-defined malignant tumours | 24 (1) | |
| Malignant endocrine tumours | 11 (1) | |
| Other‡ | 10 (1) | |
| Disease status | 8 | |
| Metastatic/disseminated | 1414 (83) | |
| Local/locally advanced | 276 (17) | |
| Survival, days from inclusion | 663§ | |
| <30 | 151 (15) | |
| 30–89 | 299 (29) | |
| 90–149 | 184 (18) | |
| 150–180 | 67 (6) | |
| >180 | 334 (32) | |
| Treatment with chemotherapy at inclusion | 3 | |
| Yes | 707 (42) | |
| No | 998 (58) | |
| Treatment with chemotherapy by the survival group (days) | ||
| <30 | 23 (15) | |
| 30–89 | 80 (27) | |
| 90–149 | 85 (46) | |
| 150–180 | 26 (39) | |
| >180 | 162 (49) | |
| Treatment with opioids at inclusion | 22 | |
| Yes | 991 (59) | |
| No | 685 (41) |
*Based on ICD-10 diagnoses from patient records.
†Including eight patients with laryngeal cancer.
‡Including malignant bone tumours (n=8), multiple primary cancers (n=2).
§Incl. 25 patients reported dead, but with no date registered.